TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16513605

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) after 4 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) after 13 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Mild heart failure without LBBB (Control group)
Number of subjects: 29
Study: 16296257

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste containing Perlite
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard silica toothpaste
Number of subjects: 20
Study: 11737007

Group type: EXPERIMENTAL
Intervention: OPFA 6 g a day for 16 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 9148018

Group type: EXPERIMENTAL
Intervention: Vaccine + Immunoglobulin (4 ml given simultaneously with the first vaccine injection)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaccine alone
Number of subjects: 80
Study: 8424426

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 42
Study: 3118589

Group type: EXPERIMENTAL
Intervention: 60 mg acemetacin t.i.d. for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20
Study: 28522745

Group type: EXPERIMENTAL
Intervention: 27 tailored cessation emails (deluxe email group (DEG))
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: 3 to 4 tailored emails with links to downloadable booklets (basic email group (BEG))
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Single non‐tailored email (single email group (SEG))
Number of subjects: 1070

Group type: COMPARATOR
Intervention: DEG compared to SEG
Number of subjects: 1070

Group type: COMPARATOR
Intervention: BEG compared to SEG
Number of subjects: 1070

Group type: COMPARATOR
Intervention: DEG compared to SEG for use of non‐medication aids
Number of subjects: 1070
Study: 29233854

Group type: EXPERIMENTAL
Intervention: Adventure video game (Night Shift)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Traditional educational apps (myATLS and Trauma Life Support MCQ Review)
Number of subjects: 368
Study: 25315663

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (n=91)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Grid laser photocoagulation (n=92)
Number of subjects: 183
Study: 23745991

Group type: EXPERIMENTAL
Intervention: Curcumin (2.0 grams orally three times per day, 6.0 grams daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20734445

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 1538
Study: 19015067

Group type: EXPERIMENTAL
Intervention: New technologies in oncological surgery
Number of subjects: 0
Study: 16961681

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 44
Study: 14515012

Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16
Study: 11046212

Group type: EXPERIMENTAL
Intervention: Pressure-control PTV at 4 cm H2O
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pressure-control PTV at 0 cm H2O
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: After extubation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pressure-control PTV at 16 cm H2O
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pressure-control PTV at 12 cm H2O
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pressure-control PTV at 8 cm H2O
Number of subjects: 7
Study: 9550777

Group type: EXPERIMENTAL
Intervention: Adjusted full intensity oral anticoagulation (target range: 3.0-4.0 INR)
Number of subjects: 8700

Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 8700

Group type: EXPERIMENTAL
Intervention: Combined therapy of low dose aspirin and adjusted low intensity oral anticoagulation (target range: 2.0-2.5 INR)
Number of subjects: 8700
Study: 8406632

Group type: EXPERIMENTAL
Intervention: Microfilariae of Wuchereria bancrofti
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Filarial disease
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Filarial endemicity
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Culex quinquefasciatus as the vector
Number of subjects: 2141
Study: 3530075

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 106

Group type: COMPARATOR
Intervention: Clindamycin/Tobramycin
Number of subjects: 106
Study: 30982349

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28067891

Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention including My Healthy Heart Profile, tailored calorie-restricted diet, and interactive prevention program.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group receiving general information about cardiovascular diseases and MetS risk factors via the website.
Number of subjects: 160
Study: 25465185

Group type: EXPERIMENTAL
Intervention: Primary tumour resection
Number of subjects: 810

Group type: COMPARATOR
Intervention: Non-resection group
Number of subjects: 810
Study: 23425152

Group type: EXPERIMENTAL
Intervention: OSFE with deproteinized bovine bone mineral (DBBM) mixed with autogenous bone chips (Group1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: OSFE without grafting (Group2)
Number of subjects: 45
Study: 21500879

Group type: EXPERIMENTAL
Intervention: Palmtop computer-delivered treatment (CDT) for smoking relapse prevention for one additional month
Number of subjects: 302

Group type: COMPARATOR
Intervention: No further computer-delivered treatment or assessment (EMA-Only)
Number of subjects: 302
Study: 18274742

Group type: EXPERIMENTAL
Intervention: MRI assessment of bone marrow edema (BME)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MRI values
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 19
Study: 16685521

Group type: EXPERIMENTAL
Intervention: Self-management interventions (education, reassurance, lifestyle modification, behavioral changes)
Number of subjects: 0
Study: 14691684

Group type: EXPERIMENTAL
Intervention: Active absorbable algal calcium (AAA Ca) 900 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO(3))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11240873

Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous pethidine (control group)
Number of subjects: 50
Study: 9250797

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus (HCV) infection
Number of subjects: 110
Study: 8318243

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous clonidine 0.3 micrograms/kg/hr and fentanyl 25 micrograms/kg
Number of subjects: 24
Study: 2948466

Group type: EXPERIMENTAL
Intervention: Immediate roentgenograms
Number of subjects: 101

Group type: COMPARATOR
Intervention: Brief educational intervention with roentgenography only for failure to improve
Number of subjects: 101

Group type: COMPARATOR
Intervention: Brief educational intervention
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups (roentgenography and education)
Number of subjects: 101
Study: 30518511

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) daily until the morning of colonoscopy
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo daily until the morning of colonoscopy
Number of subjects: 387
Study: 28500214

Group type: EXPERIMENTAL
Intervention: TeLiPro (telemedical coaching, formula diet, self-monitored blood glucose for 12 weeks)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (weighing scales and step counters, routine care)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: TeLiPro
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control
Number of subjects: 202
Study: 26030041

Group type: EXPERIMENTAL
Intervention: 8 watts RFA energy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12 watts RFA energy
Number of subjects: 60
Study: 23290991

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21355967

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 665

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/day
Number of subjects: 665
Study: 19433391

Group type: EXPERIMENTAL
Intervention: Nonpegylated liposomal doxorubicin (NLD) 60 mg/m2 every 3 weeks and trastuzumab loading dose 4 mg/kg followed by 2 mg/kg weekly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonpegylated liposomal doxorubicin (NLD) plus trastuzumab
Number of subjects: 40
Study: 17024639

Group type: EXPERIMENTAL
Intervention: Hemopure (30 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hemopure (45 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15564161

Group type: EXPERIMENTAL
Intervention: Temporary ileostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temporary colostomy
Number of subjects: 0
Study: 11393099

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (MRP) including physical therapy, nurse-supervised exercise, and discharge planning
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (MRP)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 155
Study: 9514231

Group type: EXPERIMENTAL
Intervention: Prophylactic percutaneous transluminal angioplasty (PTA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention (observation)
Number of subjects: 120
Study: 8065724

Group type: EXPERIMENTAL
Intervention: Iontophoretically applied dexamethasone in a lidocaine vehicle
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 53
Study: 2568261

Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 25
Study: 4948417

Group type: EXPERIMENTAL
Intervention: Oral streptomycin-dependent mutant Shigella vaccines
Number of subjects: 0
Study: 31124836

Group type: EXPERIMENTAL
Intervention: Alfaxalone (0.5 mg/kg bolus intravenous injection)
Number of subjects: 12
Study: 29777241

Group type: EXPERIMENTAL
Intervention: Chickpeas (GI=28, GL=14, 50g available carbohydrates)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High glycemic load meals
Number of subjects: 17

Group type: COMPARATOR
Intervention: Large potato (GI=85, GL=42, 50g carbohydrates)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pasta (GI=45, GL=42, 94g carbohydrates)
Number of subjects: 17
Study: 28814323

Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparic™) at 2 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25665908

Group type: EXPERIMENTAL
Intervention: Tooth-borne rapid maxillary expansion (hyrax)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bone-borne rapid maxillary expansion (miniscrew-implant-based)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 23968698

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BES) (n = 857)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Durable polymer sirolimus-eluting stents (SES) (n = 850)
Number of subjects: 1707
Study: 21348211

Group type: EXPERIMENTAL
Intervention: 1 IU of oxytocin followed by an infusion of 2.5 IU x h(‐1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Continuous infusion of 20 IU at a rate of 700 mlU x min(‐1) followed by 10 IU x min(‐1)
Number of subjects: 104
Study: 19485969

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg tapering to 600 mg or 1200 mg tapering to 800 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lorazepam (6 mg tapering to 4 mg)
Number of subjects: 100
Study: 16815858

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day
Number of subjects: 634

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 634
Study: 12760978

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg x2)
Number of subjects: 300
Study: 11129502

Group type: EXPERIMENTAL
Intervention: Chlorambucil therapy starting with 0.8 mg/kg/4 days, increased by 0.1 mg/kg/4 days cycle
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chlorambucil therapy
Number of subjects: 11
Study: 9329225

Group type: EXPERIMENTAL
Intervention: Pen-based computer technology for H/C-PRI assessments
Number of subjects: 476

Group type: COMPARATOR
Intervention: Usual documentation method for H/C-PRI assessments
Number of subjects: 476
Study: 8448714

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2578971

Group type: EXPERIMENTAL
Intervention: Combination of half doses of terbutaline (5 mg twice daily) and theophylline (250 mg twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Theophylline alone (500 mg twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: High-dose combination treatment (theophylline 500 mg twice daily and terbutaline 10 mg twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: High-dose combination treatment
Number of subjects: 31
Study: 30816772

Group type: EXPERIMENTAL
Intervention: Worldview-support condition
Number of subjects: 398

Group type: COMPARATOR
Intervention: Worldview-threat condition
Number of subjects: 398
Study: 30012046

Group type: EXPERIMENTAL
Intervention: Cold/Liquid Diet
Number of subjects: 194

Group type: COMPARATOR
Intervention: Regular Diet
Number of subjects: 194
Study: 26196199

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) with medium-chain triglyceride (MCT) formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral nutrition (PO) with medium-chain triglyceride (MCT) formula
Number of subjects: 15
Study: 24708781

Group type: EXPERIMENTAL
Intervention: APACHE II score-based model
Number of subjects: 1625

Group type: EXPERIMENTAL
Intervention: SAPS II score-based model
Number of subjects: 1625

Group type: EXPERIMENTAL
Intervention: SOFA score-based model
Number of subjects: 1625

Group type: EXPERIMENTAL
Intervention: Adjusted SOFA-based model (including age and GCS)
Number of subjects: 1625

Group type: EXPERIMENTAL
Intervention: Reference model (age and GCS)
Number of subjects: 1625
Study: 21763445

Group type: EXPERIMENTAL
Intervention: Probiotic Enterococcus faecium IS-27526
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16142595

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11196013

Group type: EXPERIMENTAL
Intervention: Ambient prism lenses
Number of subjects: 24
Study: 9462610

Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography (ECG)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 407
Study: 7532475

Group type: EXPERIMENTAL
Intervention: FK506/prednisone
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: FK506/azathioprine/prednisone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (not explicitly named)
Number of subjects: 204
Study: 2572477

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam-flumazenil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pethidine-diazepam-ketamine
Number of subjects: 50
Study: 799984

Group type: EXPERIMENTAL
Intervention: Nefopam 60 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Nefopam 30 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Aspirin 300 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 28681684

Group type: EXPERIMENTAL
Intervention: Association splitting (AS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study: 27886064

Group type: EXPERIMENTAL
Intervention: Probiotic supplement (1 × 10^10 CFU of multi-species probiotics)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 33
Study: 24452372

Group type: EXPERIMENTAL
Intervention: Single-session 90-min Acceptance-Based Behavioral Therapy (ABBT) workshop
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 98
Study: 22428464

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin (high HDL group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (high HDL group)
Number of subjects: 16
Study: 20862936

Group type: EXPERIMENTAL
Intervention: Regulating the Governor Vessel and Conception Vessel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine needling method
Number of subjects: 64
Study: 18490496

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate and olmesartan medoxomil (fixed-dose combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with amlodipine or olmesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration of amlodipine and olmesartan as separate entities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black race as a covariate
Number of subjects: 0
Study: 16174115

Group type: EXPERIMENTAL
Intervention: Aortic dissection (AD) surgical treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Aortic dissection (AD) medical treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Aortic intramural hematoma (IMH) follow-up outcomes
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Three-year survival rate
Number of subjects: 103
Study: 13130386

Group type: EXPERIMENTAL
Intervention: EGb 761 Ginkgo extract
Number of subjects: 0
Study: 11040176

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (1.5 mg x kg(‐1) x day(‐1)) + prednisone (40 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo + prednisone (40 mg/day)
Number of subjects: 55
Study: 8659328

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 2001777

Group type: EXPERIMENTAL
Intervention: Experimental group (physicians instructed in weight reduction methods)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Experimental and Control)
Number of subjects: 0
Study: 6650576

Group type: EXPERIMENTAL
Intervention: Label EMR (educable mentally retarded)
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Child's attractiveness and school-related traits
Number of subjects: 1114
Study: 31107249

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with a history of past TB (57 participants)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals (222 participants)
Number of subjects: 319

Group type: COMPARATOR
Intervention: HIV-uninfected individuals (97 participants)
Number of subjects: 319
Study: 30581857

Group type: EXPERIMENTAL
Intervention: i-gel®
Number of subjects: 60

Group type: COMPARATOR
Intervention: Air-Q®
Number of subjects: 60
Study: 26871523

Group type: EXPERIMENTAL
Intervention: DEX implant 0.7-mg
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: DEX implant 0.35-mg
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 1048
Study: 24178783

Group type: EXPERIMENTAL
Intervention: Wellness program intervention (12-week duration)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study: 21484965

Group type: EXPERIMENTAL
Intervention: Infliximab 5 or 10 mg/kg every 8 weeks
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Infliximab 5 or 10 mg/kg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 229
Study: 20133962

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) program, 10-month duration, three 2-hour group sessions per week
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 38
Study: 18042509

Group type: EXPERIMENTAL
Intervention: Selegiline Transdermal System (STS) 3 mg/24 h
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Selegiline Transdermal System (STS) 6 mg/24 h
Number of subjects: 86
Study: 15882297

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12498526

Group type: COMPARATOR
Intervention: Various pharmacologic therapies (acetaminophen, traditional NSAIDs, COX-2 inhibitors, intra-articular steroids, viscosupplements, glucosamine, chondroitin sulfate, capsaicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamins
Number of subjects: 0
Study: 10189601

Group type: EXPERIMENTAL
Intervention: 2-week training course on two mnemonic techniques (method of loci for words and name association technique for proper names)
Number of subjects: 268

Group type: COMPARATOR
Intervention: 2-week training course on two mnemonic techniques
Number of subjects: 268
Study: 7757311

Group type: EXPERIMENTAL
Intervention: Hydralazine (Group A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hydralazine and Propranolol (Group B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hydralazine and Pindolol (Group C)
Number of subjects: 51
Study: 2323137

Group type: EXPERIMENTAL
Intervention: Dorsal bone deficiency filled with bone cement (methylmethacrylate)
Number of subjects: 48

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 48